Sartorius Stedim Biotech: Proposals by the Board of Directors to the Annual General Shareholders’ Meeting
February 25 2016 - 5:20AM
Business Wire
- Dividend to increase by
53.8%
- Share split by 6
Regulatory News:
The Board of Directors of Sartorius Stedim Biotech S.A.
(Paris:DIM) resolved to submit a proposal to the Annual General
Shareholders' Meeting (AGM) on April 5, 2016, to pay a dividend of
€2.00 per share for fiscal 2015, up from €1.30 a year earlier. The
total profit distributed would rise from €20.0 million by 53,9% to
€30.7 million.
Moreover, the Board of Directors decided to submit resolutions
to the Shareholder Meeting to split by 6 the par value of each of
the Company’s shares (stock split). As a result, shareholders would
receive 6 shares in exchange for each share held in Sartorius
Stedim Biotech. This share split operation would be executed
without any additional costs or formalities for the shareholders
and will have no impact on their rights. The proposed stock split
is a result of the significant increase of the share price in the
past 2 years and aims at increasing the tradability of Sartorius
Stedim Biotech shares.
This press release contains statements about the future
development of the Sartorius Stedim Biotech Group. We cannot
guarantee that the content of these statements will actually apply
because these statements are based upon assumptions and estimates
that harbor certain risks and uncertainties.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of
products and services that enable the biopharmaceutical industry to
develop and manufacture drugs safely and efficiently. As a total
solutions provider, Sartorius Stedim Biotech offers a portfolio
covering nearly all steps of biopharmaceutical manufacture. The
company focuses on single-use technologies and value-added services
to meet the rapidly changing technology requirements of the
industry it serves. Headquartered in Aubagne, France, Sartorius
Stedim Biotech is quoted on the Eurolist of Euronext Paris. With
its own manufacturing and R&D sites in Europe, North America
and Asia and a global network of sales companies, Sartorius Stedim
Biotech has a global reach. The company employs approx. 4,200
people, and in 2015 earned sales revenue of 884.3 million
euros.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160225005698/en/
Sartorius Stedim BiotechPetra KirchhoffVice President of
Corporate
Communications+49(0)551.308.1686petra.kirchhoff@sartorius.com
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Nov 2024 to Dec 2024
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about WisdomTree International MidCap Dividend Fund (American Stock Exchange): 0 recent articles
More Wisdomtree International Midcap Dividend Fund News Articles